ASX RELEASE

12 September 2016

ASX: NOX

Noxopharm Limited

ABN 50 608 966 123

Registered Office:
Suite 1 Level 6
50 Queen St
Melbourne VIC 3000
Australia

NOXOPHARM CORPORATE PRESENTATION, SEPTEMBER 2016

Ahead of a roadshow commencing 12 September in Asia, Noxopharm has today released an updated corporate presentation incorporating expansion of its NOX66 clinical program into both chemotherapy and radiotherapy indications as announced recently.

The Corporate presentation can be found on the Company's website www.noxopharm.com

About NOX66

NOX66 is an innovative dosage formulation of idronoxil, a compound that down-regulates pro-survival mechanisms in cancer cells, including the cell's ability to establish and maintain a range of drug-resistance mechanisms. The primary target of idronoxil is tumour-specific external NADH oxidase 2 (or ENOX2), the protein responsible for maintaining the transmembrane electron potential in the cancer cell's plasma membrane. Loss of this potential inhibits the ability of the cancer cell to maintain a wide range of pro-survival mechanisms. NOX66 has been developed specifically to protect idronoxil from Phase 2 metabolism in the human body, and in so doing to increase the bio-availability of idronoxil to cancer cells.

About Noxopharm

Noxopharm is an Australian drug development company with offices in Melbourne and Sydney. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development in an R&D program.

ENQUIRIES: Prue Kelly : info@noxopharm.com **Phone: + 61 2 9144 2223**

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as "aim", "anticipate", "assume", "believe", "continue", "could", "estimate", "expect", "intend", "may", "plan", "predict", "project", "plan", "should", "target", "will" or "would" or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company's control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

NOXOPHARM

Corporate Presentation, Sept 2016

ASX: NOX

The problem

- Once a cancer becomes metastatic, death is the usual eventual outcome
- Treatment fails because cancer cells have become resistant to standard therapies
- Death occurs because the patient runs out of treatment options
- Resistance to chemotherapy and radiotherapy is the single largest problem facing the management of cancer

NOXOPHARM

Our objective

- To bring to market a proprietary drug that overturns cancer cell resistance mechanisms in a potent and highly selective way
- To restore responsiveness to standard **chemotherapy** and **radiotherapy**
- To provide treatment options for the elderly and frail, and the growing population of patients who elect not to undergo damaging therapies

NOXOPHARM

Our means

NOX66
An innovative form of idronoxil

- **Idronoxil** is the most potent inhibitor of **cancer cell resistance mechanisms**
- **Idronoxil** works for both **chemotherapy** and **radiotherapy**
- **Idronoxil** is **highly selective** for cancer cells
- **NOX66** - designed to ensure idronoxil reaches the cancer in an **active form**

NOXOPHARM

Our vision

- To have a first-in-class drug meeting a substantial unmet clinical need
- To dominate the field in major drug territories with IP protection
- To become a global biopharmaceutical company with a suite of drugs focused on cancer cell resistance mechanisms

NOXOPHARM

Idronoxil



Overturns resistance to all major cytotoxic drugs

Cisplatin	Carboplatin
Paclitaxel	Docetaxel
Gemcitabine	Doxrubicin
Topotecan	

Overturns resistance in all forms of cancers tested

Ovarian	Melanoma
Prostate	Head & neck
Pancreatic	

No evidence of toxicity

Laboratory
Animals
Humans

Source: Brown D et al (2008) Drugs of the Future 33, 844

NOXOPHARM

Clinical Program
Chemotherapy

Cytotoxic chemotherapy

main front-line therapy for most forms of life-threatening cancers



NOXOPHARM

Objectives

Cytotoxic chemotherapy

- **Achieve responses in cancers with inherent resistance (*eg. pancreatic cancer, malignant melanoma, brain cancer*)**
- **Achieve responses in cancers with acquired resistance**
- **Lower dosages of chemotherapy to provide safer therapy**
- **Make chemotherapy an option for patients who elect not to be treated**
- **Make effective chemotherapy feasible in elderly/frail patients**

NOXOPHARM

Phase I/II Clinical Study
Design

Number of sites	2
Territory	Georgia
Commence	Q4 2016
Patients	Solid tumours that have failed to respond to standard therapies
Number of patients	Minimum 15. Maximum 35
Phase 1a	14-days NOX66 monotherapy
Phase 1b	6 months combination therapy: NOX66 + carboplatin. Carboplatin = low dose (AUC=4) for 3 months; standard dose (AUC=6) for next 3 months
Phase 2a	Maximum 2 cohorts (each 10 patients) of selective cancer types of selective NOX66 + carboplatin dosage combination

NOXOPHARM

Phase I/II Clinical Study
Potential outcomes

Safety	• Confirmation that NOX66 does not exacerbate carboplatin toxicity
Clinical benefit	• Reversal of resistance to carboplatin in cancers with inherent drug resistance *(eg. pancreatic cancer, lung cancer)* • Reversal of resistance to carboplatin in cancers with acquired resistance *(eg. ovarian cancer, breast cancer)*
Lowered cytotoxic drug dosage	• Confirm that NOX66 will allow the dosage of carboplatin to be lowered to a non-toxic level without compromising its anti-cancer effect

NOXOPHARM

Clinical Program
Radiotherapy



Radiation therapy

Front-line or second-line therapy for many common forms of cancer

NOXOPHARM

Phase Ib Clinical Study
Design/potential outcomes

Status	• 2 proposed studies • Currently in planning • Projected start 4Q16 & 1Q17
Proposed design	• Specific tumour type per study • Palliative radiotherapy to selective lesions + NOX66 • 2 weeks Rx. • 2-3 months response assessment
Hypothesised outcomes	• NOX66 will inhibit DNA repair mechanisms and radio-resistance • NOX66 will enable palliative (non-curative) dosages of radiotherapy to deliver significant tumour responses

NOXOPHARM

Indicative timelines



IP position

Idronoxil	Structure not patentable. First described by G. Kelly in 1994.
Patent lodgement	Family of provisional patents lodged. Claims revolve around innovative formulation designed to block Phase 2 metabolism and conserve bio-activity
2nd and 3rd generation products	R&D programs initiated with intention of delivering a family of therapeutics with specific abilities to cancel resistance mechanisms

NOXOPHARM

Experienced team



Graham Kelly *PhD*
Managing Director

- Head of research team at University of Sydney that discovered idronoxil in 1992
- Founded (CEO) Novogen Ltd (ASX 1994; NASDAQ 1998). Executive Director 1994-2006)
- Chairman of Marshall Edwards Inc(AIM 2001; NASDAQ 2003)
- CEO/Executive Chairman Novogen Ltd 2012-2015
- Founded Noxopharm October 2015

Dr Ian Dixon *PhD, MBA*
Non-Executive Director

- Over 20 years' experience in the biotechnology and medical device industries and was founder/co-founder of numerous successful technology companies, including Cynata Ltd, Genscreen Pty Ltd and August Therapeutics.
- Previously a non-executive Director of Cell Therapies Pty Ltd, and Director of the Product Group at Invetech, now part of Danaher Corporation (NYSE: DHR).
- Led early development of the anti-tropomyosin drug technology that his company licensed to Novogen Ltd.



Peter Marks
Non-Executive Chairman

- 30+ years experience in corporate finance, specializing in capital raisings (for listed and unlisted companies), underwriting, IPOs and venture capital transactions.
- Participated in over$2B in public and private capital raised.
- Executive and Non-Executive Director of a number of listed entities on the ASX and AIM

Phillip Hains
Company Secretary

- Phillip holds a Masters of Business Administration from RMIT and a Public Practice Certificate from the Institute of Chartered Accountants.

  As a chartered accountant, Phillip operates his own specialist public practice, The CFO Solution, providing back-office support, financial reporting and compliance systems for public companies.

  Phillip has over 20 years' experience in providing businesses with accounting, administration, compliance and general management services.

Key metrics

Shares outstanding	**75M** : 30M free; 45M escrowed (July 2019)
Other	22.5M options ($0.30) (2021) 10M performance shares ($50M market cap) (2021)
Cash position	$6M IPO (9 Aug 2016) $5M (Sept 2016)

NOXOPHARM

Concluding Remarks

Company Aim

To overturn resistance to the most commonly-used chemotherapies & radiotherapy



- Improved response rates in most forms of solid cancers
- Allow drug and radiotherapy dose rates to be lowered to reduce toxicity
- Permit effective therapy in elderly/frail patients
- Provide safe therapy to patients electing not to have therapy

Value drivers

Large market size	Lack of competition	Experience	Clinic-ready	Expeditious clinical plan
Substantial unmet need for most patients with solid cancers	No current drug or known drug in development with same ability to reverse cancer resistance mechanisms	Over 20 years' experience with this technology generally and this drug specifically	Phase 1 study to commence in 4Q16	Indication of efficacy designed to be available within 18 months

Key Messages

- Resistance to chemotherapy/radiotherapy remains the most pressing and largest problem facing patients
- No drug has come to market that successfully treats this problem
- WE EXPECT TO KNOW WITHIN 12 MONTHS OF THE SUCCESS OF OUR MISSION IN RADIOTHERAPY
- WE EXPECT TO KNOW WITHIN 18 MONTHS OF THE SUCCESS OF OUR MISSION IN CHEMOTHERAPY
- A SUCCESSFUL OUTCOME ISA MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET

✓ Lean, focused operation

✓ 5 key inflection points anticipated within next 18 months

✓ Potential for NOX66 to become standard of care

Disclaimer

- *This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.*
- *This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.*
- *This presentation may contain forward-looking statements which are identified by words such as 'may', 'could', 'believes', 'estimates', 'targets', 'expects', or 'intends'and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.*
- *Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.*
- *Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.*

Contact

Dr Graham Kelly
Chief Executive Officer

graham.kelly@noxopharm.com